[Effect of astragalus injection combined with chemotherapy on quality of life in patients with advanced non-small cell lung cancer]

source extracted confidence: high 2026-04-09
#adult #aged #antineoplastic-combined-chemotherapy-protocols #astragalus-propinquus #carcinoma-non-small-cell-lung

[Effect of astragalus injection combined with chemotherapy on quality of life in patients with advanced non-small cell lung cancer]

Zou et al., 2003 | Zhongguo Zhong Xi Yi Jie He Za Zhi | Rct

Citation

Zou Yu-he, Liu Xue-mei. [Effect of astragalus injection combined with chemotherapy on quality of life in patients with advanced non-small cell lung cancer]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2003-Oct;23(10):733-5

Abstract

OBJECTIVE: To observe the effect of Astragalus injection (AI) combined with chemotherapy on quality of life (QOF) in patients with advanced non-small cell lung caner (NSCLC). METHODS: Sixty-NSCLC patients were randomly divided into the treated group (n = 30, treated with AI combined with chemotherapy) and the control group (n = 30, treated with chemotherapy alone). Chemotherapy of MVP protocol was applied to both groups. AI was supplemented to the treated group by intravenous dripping 60 ml per day. Treatment of 21-28 days as one treatment cycle, and 2-3 treatment cycles were applied. RESULTS: The effective rate in the treated group was 40.0% and in the control group was 36.7%, the mean remission rate in the treated and control group was 5.4 months and 3.3 months, the median survival period 11 months and 7 months, and the 1-year survival rate 46.75% and 30.0%, respectively, the differences of these indexes between the two groups were all significant (P < 0.05). Moreover, the clinical improving rate and QOF elevation rate in the treated group was 80.4% and 43.3%, as compared with those in the control group (50.0% and 23.3% respectively), the difference was also significant (P < 0.01). CONCLUSION: AI combined with chemotherapy can significantly improve the QOF in NSCLC patients of advanced stage.

Key Findings

The effective rate in the treated group was 40.0% and in the control group was 36.7%, the mean remission rate in the treated and control group was 5.4 months and 3.3 months, the median survival period 11 months and 7 months, and the 1-year survival rate 46.75% and 30.0%, respectively, the differences of these indexes between the two groups were all significant (P < 0.05). Moreover, the clinical improving rate and QOF elevation rate in the treated group was 80.4% and 43.3%, as compared with those

Outcomes Measured

  • Requires manual extraction

Population

Field Value
Population advanced non
Sample Size 30
Age Range See abstract
Condition See abstract

MeSH Terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols
  • Astragalus propinquus
  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma, Squamous Cell
  • Cisplatin
  • Drug Therapy, Combination
  • Drugs, Chinese Herbal
  • Female
  • Humans
  • Lung Neoplasms
  • Male
  • Middle Aged
  • Mitomycins
  • Phytotherapy
  • Quality of Life
  • Vinblastine

Evidence Classification

  • Level: Rct
  • Publication Types: Clinical Trial, Journal Article, Randomized Controlled Trial
  • Vertical: astragalus

Provenance

  • PMID: 14626183
  • DOI: (not available)
  • PMCID: Not in PMC
  • Verified: 2026-04-09 via PubMed E-utilities API

Source extracted via PubMed E-utilities API on 2026-04-09